Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) Overview | 9 | 1 |
| Therapeutics Development | 10 | 4 |
| Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) Products under Development by Stage of Development | 10 | 1 |
| Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) Products under Development by Therapy Area | 11 | 1 |
| Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) Products under Development by Indication | 12 | 2 |
| Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) Pipeline Products Glance | 14 | 3 |
| Late Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Unknown Stage Products | 16 | 1 |
| Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) Products under Development by Companies | 17 | 4 |
| Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) Products under Development by Universities/Institutes | 21 | 2 |
| Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) Therapeutics Assessment | 23 | 7 |
| Assessment by Monotherapy/Combination Products | 23 | 1 |
| Assessment by Mechanism of Action | 24 | 2 |
| Assessment by Route of Administration | 26 | 2 |
| Assessment by Molecule Type | 28 | 2 |
| Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) Companies Involved in Therapeutics Development | 30 | 12 |
| Adamis Pharmaceuticals Corporation | 30 | 1 |
| Argos Therapeutics, Inc. | 31 | 1 |
| Asterias Biotherapeutics, Inc. | 32 | 1 |
| e-Therapeutics Plc | 33 | 1 |
| F. Hoffmann-La Roche Ltd. | 34 | 1 |
| Inovio Pharmaceuticals, Inc. | 35 | 1 |
| Invectys SA | 36 | 1 |
| Johnson &Johnson | 37 | 1 |
| Komipharm International Co., Ltd. | 38 | 1 |
| Mediolanum farmaceutici S.p.A. | 39 | 1 |
| Ultimovacs AS | 40 | 1 |
| Vaxon Biotech | 41 | 1 |
| Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) Drug Profiles | 42 | 42 |
| ASTVAC-1 Drug Profile | 42 | 2 |
| ASTVAC-2 Drug Profile | 44 | 2 |
| ETS-2300 Drug Profile | 46 | 1 |
| Gene Therapy to Activate Telomerase for Alzheimer's Disease Drug Profile | 47 | 1 |
| Gene Therapy to Activate Telomerase for Alzheimer s Disease and Atherosclerosis Drug Profile | 48 | 1 |
| Gene Therapy to Activate Telomerase for Aplastic Anemia Drug Profile | 49 | 1 |
| GX-301 Drug Profile | 50 | 1 |
| imetelstat sodium Drug Profile | 51 | 7 |
| INO-1400 Drug Profile | 58 | 1 |
| INO-5400 Drug Profile | 59 | 1 |
| INVAC-1 Drug Profile | 60 | 1 |
| KML-001 Drug Profile | 61 | 2 |
| rocapuldencel-T Drug Profile | 63 | 7 |
| Small Molecule to Target Telomerase for Lung Cancer Drug Profile | 70 | 1 |
| Small Molecules to Activate Telomerase for ALS, GVHD, Ageing and Leukemia Drug Profile | 71 | 1 |
| TeloB-VAX Drug Profile | 72 | 1 |
| tertomotide Drug Profile | 73 | 2 |
| UCPVax Drug Profile | 75 | 1 |
| UV-1 Drug Profile | 76 | 1 |
| Vaccine to Target Telomerase for Oncology Drug Profile | 77 | 1 |
| Vaccine to Target Telomerase for Solid Tumor Drug Profile | 78 | 1 |
| Vbx-016 Drug Profile | 79 | 1 |
| Vbx-026 Drug Profile | 80 | 1 |
| Vx-001 Drug Profile | 81 | 2 |
| Vx-006 Drug Profile | 83 | 1 |
| Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) Dormant Projects | 84 | 4 |
| Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) Discontinued Products | 88 | 4 |
| Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) Featured News &Press Releases | 92 | 14 |
| Jun 13, 2016: Independent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 in Metastatic Renal Cell Carcinoma Following Interim Data Review | 92 | 1 |
| May 02, 2016: Asterias Biotherapeutics Announces Oral Presentation at ASGCT 19th Annual Meeting | 92 | 1 |
| Apr 20, 2016: Geron Announces Two Imetelstat Poster Presentations at the American Association for Cancer Research Annual Meeting | 93 | 2 |
| Mar 23, 2016: Argos Therapeutics Announces Initiation of a Phase 2 Clinical Trial of AGS-003 for the Treatment of Non-small Cell Lung Cancer in Combination with Standard-of-Care Chemotherapy | 95 | 1 |
| Mar 02, 2016: New trial launched to test cancer vaccine | 95 | 2 |
| Feb 24, 2016: Asterias Biotherapeutics Announces Successful End-of-Phase 2 Meeting with FDA for AST-VAC1 | 97 | 1 |
| Jan 21, 2016: Asterias Biotherapeutics Announces Completion of Transfer of AST-VAC2 Manufacturing Process to Cancer Research UK as Milestone Towards Initiating Phase 1/2 Clinical Trial | 98 | 1 |
| Jan 14, 2016: Geron Announces Initiation of Janssen Phase 2/3 Clinical Trial of Imetelstat in Myelodysplastic Syndromes | 99 | 1 |
| Dec 10, 2015: Independent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 for Metastatic Renal Cell Carcinoma Following Second Planned Interim Analysis | 100 | 1 |
| Nov 05, 2015: Geron Announces Presentations at American Society of Hematology Annual Meeting | 100 | 1 |
| Nov 05, 2015: Janssen to Present Posters on Imetelstat at the 2015 American Society of Hematology Annual Meeting | 101 | 1 |
| Oct 30, 2015: Invectys starts the third dose level of its phase I clinical trial evaluating INVAC-1, an innovative anti-cancer therapeutic vaccine | 102 | 1 |
| Sep 16, 2015: Geron Announces Initiation of Janssen Phase 2 Clinical Trial of Imetelstat in Myelofibrosis | 103 | 1 |
| Sep 02, 2015: Dual Publications in the New England Journal of Medicine Highlight Transformative Potential of Imetelstat in Hematologic Myeloid Malignancies | 103 | 1 |
| Aug 10, 2015: Argos Therapeutics Announces Pilot Clinical Trial of AGS-003 as Neoadjuvant Immunotherapy for Localized Renal Cell Carcinoma | 104 | 2 |
| Appendix | 106 | 2 |
| Methodology | 106 | 1 |
| Coverage | 106 | 1 |
| Secondary Research | 106 | 1 |
| Primary Research | 106 | 1 |
| Expert Panel Validation | 106 | 1 |
| Contact Us | 106 | 1 |
| Disclaimer | 107 | 1 |